首页> 外文期刊>Neuroscience Letters: An International Multidisciplinary Journal Devoted to the Rapid Publication of Basic Research in the Brain Sciences >Neuroprotective effects and dynamic expressions of MMP9 and TIMP1 associated with atorvastatin pretreatment in ischemia-reperfusion rats
【24h】

Neuroprotective effects and dynamic expressions of MMP9 and TIMP1 associated with atorvastatin pretreatment in ischemia-reperfusion rats

机译:与缺血再灌注大鼠阿托伐他汀预处理的MMP9和MMP9和TIMP1的神经保护作用和动态表达

获取原文
获取原文并翻译 | 示例
           

摘要

Atorvastatin has been reported to ameliorate ischemic brain damage after stroke, but the underlying mechanisms are not clear. This study investigated the effect of atorvastatin on dynamic expressions of MMP9 and TIMP1 in rats after cerebral ischemia reperfusion (I/R). Atorvastatin (5 mg kg(-1) d(-1)) or vehicle was administered orally to rats for 21d before middle cerebral artery occlusion (MCAo) for 2 h, with perfusion at 3-, 12-, 24-, 48-, or 96-h thereafter. To evaluate functional outcome, a 5-point behavioral rating scale was performed. Ischemic lesion volume was assessed via triphenyl tetrazolium chloride (TTC) staining. mRNA levels of MMP-9 and TIMP-1 were detected by reverse transcription-PCR, and protein levels of MMP-9 and TIMP-1 were measured by immunohistochemical SABC method. At all reperfusion time points, atorvastatin pretreatment was associated with significantly (P<0.05) improved neurological function and reduced brain infarct sizes compared with vehicle treatment, and MMP9 levels were significantly (P<0.05) lower and TIMP1 levels were significantly (P<0.05) higher in both mRNA and protein levels. In conclusion, Oral administration of atorvastatin before stroke may reduce the severity in I/R injury and improve neurological outcome by lowering MMP9 levels and elevating TIMP1 levels. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
机译:据报道,阿托伐他汀在中风后改善了缺血性脑损伤,但潜在的机制尚不清楚。本研究研究了阿托伐他汀对大鼠脑缺血再灌注(I / R)后大鼠MMP9和TIMP1的动态表达的影响。阿托伐他汀(5mg kg(-1)d(-1)d(-1))或载体在中间脑动脉闭塞(MCAO)之前对21d的大鼠施用2小时,在3-,12-,24-,48-此后的96-h。为了评估功能结果,进行了5点行为评级规模。通过三苯基四唑氯化物(TTC)染色评估缺血性病变体积。通过逆转录PCR检测MMP-9和TIMP-1的mRNA水平,通过免疫组织化学SABC方法测量MMP-9和TIMP-1的蛋白质水平。在所有再灌注时间点时,阿托伐他汀预处理与显着相关(P <0.05)改善的神经功能,与载体治疗相比,脑梗塞减少的脑梗塞尺寸,MMP9水平显着(P <0.05),较低,TIMP1水平显着显着(P <0.05 )mRNA和蛋白质水平较高。总之,口腔前的口服施用阿托伐他汀可以降低I / R损伤的严重程度,并通过降低MMP9水平并提高TIMP1水平来改善神经系统结果。 (c)2015 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号